PITTSBURGH, April 20 /CNW/ -- Mylan Inc. (Nasdaq: MYL) today announced
that Matrix Laboratories Limited, its India-based subsidiary in which it holds
a 71.2% controlling interest, has been selected by the Clinton HIV/AIDS
Initiative (CHAI) under its UNITAID-funded projects as the primary supplier of
five antiretroviral (ARV) drugs used in second-line HIV/AIDS treatment
regimens. Matrix also has been selected as the primary supplier of seven ARVs
used for pediatric treatment.
Mylan Vice Chairman and CEO Robert J. Coury said: "I would like to
congratulate UNITAID and CHAI on the tremendous impact they have made in
fighting the HIV/AIDS epidemic, which continues to present significant
challenges on a global scale. Facilitating patient access to affordable,
quality treatments has helped transform AIDS from a fatal illness into a
manageable chronic condition. Ensuring that access to these treatments
continues to expand is a critical piece of solving this crisis. Mylan and
Matrix are proud to play an important role in these efforts by supplying a
broad portfolio of low cost, high quality products, and we remain committed to
further increasing access for patients in developing countries through our
innovative science and expertise."
According to the Joint United Nations Program on AIDS (UNAIDS), an
estimated 33 million people in the world are infected with HIV, and more than
90% of those patients live in the developing world. Less than 4 million
patients globally are receiving treatment; however, approximately 30% of
patients in developing countries depend on Matrix ARV products.
Mylan's Chief Operating Officer Heather Bresch added: "Matrix has done a
remarkable job developing a world-class ARV business in just a few years.
Their emphasis on producing affordable products has significantly reduced the
average annual cost per patient of AIDS treatment. I also would like to
recognize the efforts of UNITAID and CHAI, which have both worked diligently
to increase the supply of effective medicines. Significant progress has been
made in dramatically reducing the costs of second-line treatments, and our
partnerships with CHAI and other donor organizations will allow us to further
reduce the costs of treatments for children. However, there still is much more
work to be done. Mylan and Matrix intend to advance our leadership role and
partnerships by continuing to produce affordable, high quality ARV products
and getting them to those in need."
Matrix's second-line products selected for the 2009 UNITAID-CHAI projects
include heat-stable Lopinavir/Ritonavir, Tenofovir and two fixed-dose
combinations that use Tenofovir. The seven ARVs for which Matrix was selected
under the UNITAID Pediatric Project include several first-line fixed-dose
combinations. Patients often use second-line therapies if and when they
develop resistance to initially prescribed treatments or experience clinical
failures. Fixed-dose combinations are multiple ARV drugs combined into a
UNITAID is an international drug purchase facility, established to
provide long-term, sustainable and predictable funding to increase access and
reduce prices of quality drugs and diagnostics for the treatment of HIV/AIDS,
malaria and tuberculosis in developing countries. UNITAID-CHAI projects supply
ARVs for pediatric and adult second-line treatment in 42 developing countries.
The group's efforts account for approximately 75% of funding spent on
pediatric ARV treatments and 50% of funding spent on second-line ARV
treatments in generic accessible markets.
Matrix and ARVs
Matrix is one of the world's largest producers of API used to manufacture
ARVs. In 2007, Matrix launched its FDF ARV franchise and, only two years
later, offers 29 FDFs, including most of the currently used first- and
second-line treatments. All of Matrix's ARV facilities in India meet World
Health Organization (WHO) and U.S. Food and Drug Administration (FDA) quality
standards, and the company has strong partnerships with all major funding
agencies involved in the procurement of ARVs. In addition to its ARV
capabilities, Matrix is the world's third largest manufacturer of API used to
produce a broad range of therapies.
Mylan Inc., which provides products to customers in more than 140
countries and territories, ranks among the leading diversified generics and
specialty pharmaceutical companies in the world. The company maintains one of
the industry's broadest - and highest quality - product portfolios, supported
by a robust product pipeline; owns a controlling interest in the world's third
largest active pharmaceutical ingredient manufacturer; and operates a
specialty business focused on respiratory and allergy therapies. For more
information, visit www.mylan.com.
For further information:
For further information: Media, Michael Laffin, +1-724-514-1968, or
Investors, Dan Crookshank, +1-724-514-1813, both of Mylan Inc. Web Site: